Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab switch study in rheumatoid arthritis after inadequate control with etanercept or adalimumab
2009-010582-23Phase 3Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of golimumab in rheumatoid arthritis (RA) (2 cohorts), sponsored by Janssen Biologics B.V. Primary endpoint: ACR20 response at Week 14. Started Sep 2009; status: completed.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-010582-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010582-23.